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Abstract Despite improvements in systemic chemother-
apy (CT), the prognosis of metastatic adenocarcinoma of
the gastroesophageal junction remains poor. Over the
years, new targeting agents have become available and
were tested, with or without CT, in first or subsequent lines
of therapy. The epidermal growth factor receptor family
was targeted with monoclonal antibodies (MoAbs) (tras-
tuzumab, cetuximab, panitumumab) and tyrosin kinase
inhibitors (TKIs) (lapatinib, erlotinib, gefitinib). Only
trastuzumab, in combination with cisplatin and fluoropy-
rimidines, significantly improved overall survival (OS) in
first-line therapy (13.8 vs. 11.1 months). Angiogenesis also
was targeted with MoAbs (bevacizumab and ramu-
cirumab); ramucirumab, a vascular endothelial growth
factor-receptor 2 antagonist, enhanced OS in two phase III
studies in the first (9.6 vs. 7.4 months) and subsequent lines
of treatment (5.2 vs. 3.8 months), while the bevacizumab
study was negative. TKIs (sunitinib, sorafenib, regorafenib,
apatinib) were tested in this setting in phase II studies in the
second/third line, only showing modest antitumor activity.
The hepatocyte growth factor receptor (MET) was targeted
in untreated patients in a phase III trial with MoAb rilo-
tumumab, with or without CT, but the study was stopped
because of mortality excess in the rilotumumab arm.
Mammalian target of rapamycin (MTOR) pathway
inhibition with everolimus was tested in pretreated patients
in a placebo-controlled phase III trial who failed to
improve OS (5.4 vs. 4.3 months). In conclusion, consid-
ering the modest survival gain obtained overall, the high
cost of these therapies and the quality of life issue must be
primarily considered in treating these patients.
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Introduction
In metastatic adenocarcinoma of the gastroesophageal
junction (GEJA) chemotherapy has long been considered
the cornerstone treatment; nevertheless, studies devoted to
this subset are lacking because these patients were enrolled
in gastric cancer (GC) trials that were statistically
unpowered to examine the two entities separately. In ran-
domized clinical trials of GC, GEJA represented 13–29 %
of the study population and the 2-year survival rate did not
exceed 20 % [1]. Anyway, EJGA should be considered a
distinct entity from non-cardia GC. The higher incidence of
EJGA in Western countries confirms that GEJA and non-
cardia GC are related to risk factors having different dis-
tributions across the world. Gastroesophageal reflux and
Barret metaplasia are risk factors for EJGA [2], while
gastric atrophia due to Helicobacter pylori infection is the
main risk factor for non-cardia GC. From the clinico-
pathological point of view, GEJA demonstrated a higher
aggressiveness compared to non-cardia GC, more
advanced TNM stage, younger age, higher recurrence rate
and lower survival rates [3–5].
Some studies report that mutations and copy number
alterations differ between GEJA and non-cardia GC.
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Tumors with chromosomal instability, marked aneuploidy
and amplification of receptor tyrosine kinases showed
elevated frequency in the gastroesophageal junction. TP53
and RAS mutations were also most frequent in GEJA,
while tumors arising from the mid and distal stomach were
more likely to have PIK3CA, RHOA and Wnt pathway
mutations, microsatellite instability (MSI) and positivity
for Epstein-Barr virus [5, 6]. Another strategy for molec-
ular classification is based on the gene expression profile.
One study used gene expression data and found different
clinical outcomes in relation to four different patterns of
molecular alterations. The mesenchymal-like type had the
worst prognosis; the MSI group had the best overall
prognosis, while the TP53-active and TP53-inactive groups
presented an intermediate prognosis. The TP53-active
subtype was most frequently found in GEJA [7]. Another
study identified 511 genes with dysregulated expression in
cardia or non-cardia GC; of these genes, about one-half
were dysregulated in both cardia and non-cardia, one-
fourth in cardia and one-fourth in non-cardia only. Some
genes were associated with survival; the most significant
P values were documented for ALDH3A1 and TRIP13
genes in GEJA, while ADA, ADH1, AKR1B10, ATP4B,
LHFP, TFF2 and LIPF genes in non-cardia cancer [8].
Amplification of the HER2 gene is found in about 15–20 %
of the patients and seems associated with a negative
prognostic role; higher expression was documented in the
GEJ (33.2 %) and proximal part compared to distal parts of
the stomach [9].
A recent report from a German database on GEJA and
GC for the years 2006–2009 showed that monotherapy,
doublet and triplet chemotherapies were used in about 10,
60 and 30 % of the patients, respectively; older or less fit
patients were more likely to receive monotherapy or dou-
blets, while younger patients more commonly received
triplets (40.2 vs. 20.8 %). Consistent with other reports,
median age was 67 years with male preponderance (64 %).
This analysis reflects the transfer of study data into clinical
practice, although the impact on survival was not investi-
gated [10]. Over the years, an increasing number of tar-
geting agents has become available for many types of
tumors, and these were also tested in GC and GEJA. In this
review, we summarize the results of clinical studies testing
targeted therapies in GEJA by separately analyzing tar-
geted oncogenic pathways (Fig. 1).
Targeting the epidermal growth factor family
The epidermal growth factor receptor (EGFR) family is
composed of four members: HER1 (also known as EGFR/
ErbB1), HER2, HER3 (also named ErbB-3) and HER4
(also termed ErbB-4). These receptors share the same
molecular structure with an extracellular ligand-binding
domain, a short transmembrane domain and an intracellular
domain with tyrosin kinase (TK) activity (except the
HER3). The binding of different ligands to the extracellular
domain triggers a signal transduction cascade that can
influence many aspects of tumor cell biology, including
cell proliferation, apoptosis, adhesion, migration and dif-
ferentiation. Ligand binding induces EGFR homodimer-
ization as well as heterodimerization with other types of
HER proteins. GFR signaling can be deregulated in cancer
by various mechanisms (i.e., increased receptor expression,
autocrine or paracrine ligand secretion and somatic muta-
tions). In contrast to colorectal and lung cancer, KRAS
mutation status and EGFR mutations do not seem to play a
relevant role.
Clinical strategies have been developed to target GFR in
gastrointestinal cancers such as:
1. Monoclonal antibody (moAb) binding epitopes of the
extracellular domain of GFR;
2. MoAbs devoted to neutralizing ligands [i.e., vascular
endothelial growth factor (VEGF)];
3. Small molecules that cross the cell membrane and
interfere with the enzymatic function of TK receptor or
intracellular signaling molecules able to inhibit aber-
rant signal transduction.
(a) The EGFR (HER1/EGFR/ErbB1) is a cell surface
protein that binds to epidermal growth factor. Binding of
the protein to the ligand induces receptor dimerization and
tyrosine autophosphorylation leading to cell proliferation.
EGFR is approximately expressed by immunohistochem-
istry (IHC) in 30–70 % of esophageal adenocarcinomas
(ADs) and may correlate with a dismal survival. EGFR
inhibition was attempted using moAbs cetuximab, panitu-
mumab, matuzumab and nimotuzumab, and the results
were reported in several phase I–II studies (Table 1)
[11–22].
The AGITG ATTAX3 study [21], a randomized phase II
study, compared chemotherapy (weekly docetaxel, cis-
platin and fluoropyrimidine) with and without panitu-
mumab. The addition of panitumumab to docetaxel-based
chemotherapy did not improve efficacy, but increased some
G3/4 toxicities. A safety alert from the REAL-3 study [23]
prompted an unplanned review of the data; although no
evidence of adverse outcomes was detected in the experi-
mental arm, the study was stopped after enrolling 77
patients (38 with panitumumab).
A randomized phase II trial [22] evaluated nimotuzumab
in association with irinotecan versus irinotecan in second-
line therapy; the primary end point (PFS) was not met, but
the combination showed potential outcome improvement in
the EGFR 2?/3? subset. On the whole, data from phase II
showed modest survival gain; nevertheless panitumumab
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and cetuximab underwent evaluation in the REAL-3 [23]
and EXPAND [24] phase III randomized clinical trials
(Table 2). A nimotuzumab phase III study is ongoing in
recurrent Asian patients overexpressing EGFR 2?/3? in
IHC. The REAL-3 trial [23] compared a standard EOX
regimen (epirubicin, oxaliplatin, capecitabine) with a
modified EOX (mEOX) associated with panitumumab;
indeed, the panitumumab arm was detrimental in terms of
OS, which was the primary end point.
In an exploratory analysis of 276 patients receiving
panitumumab, the development of any grade of rash (79 %
of the patients) was associated with significantly longer OS
and PFS: median OS was 10.3 vs. 4.3 months and median
PFS was 6.8 vs. 3.7 months in patients with or without
rash, respectively (p\ 0.0001). Negative results were also
obtained in the EXPAND trial [24], which tested the
combination of capecitabine and cisplatin with or without
cetuximab. The addition of cetuximab failed to improve the
PFS (the primary end point), OS and response rate (RR). In
a predefined subset analysis, irrespective of the treatment
arm, patients with HER2-negative tumor (535 patients)
showed increased risk of death (HR 1.55, 95 % CI
1.24–1.94) and reduced RR (HR 0.47, 95 % CI 0.31–0.72)
compared with patients with HER2-positive tumors (144
Fig. 1 Targeted oncogenic pathways in advanced gastroesophageal adenocarcinoma
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patients). Tumor EGFR expression was generally low;
however, using a series of cutoff points from an IHC score,
there was a tendency for improved OS, PFS and RR when
adding cetuximab to CT in patients with high tumor EGFR
IHC scores. This finding suggests a benefit from adding
cetuximab to CT in a small proportion of patients with high
EGFR tumor expression [25].
(b) The clinical role of HER2 overexpression was been
first evaluated in the ToGA trial [26]. The study enrolled
594 patients (about 18 % with GEJA) and compared cis-
platin-fluoropyrimidine chemotherapy alone or with tras-
tuzumab with OS as the primary endpoint. All patients had
immunohistochemical overexpression of HER2 or gene
amplification by FISH. Among the screened tumors, HER2
Table 1 Phase I–II studies with anti-EGFR moAbs
Ref. Patients Setting Population Therapy Outcome
Pinto et al. [11] 72 Metastatic
1st line
Gastric and GEJ AD (18 %) Cetuximab ? Cisplatin and
docetaxel
RR = 41 %
mTTP = 5 mo
mOS = 9 mo
Pinto et al. [12] 38 Metastatic
1st line
Gastric and GEJ AD (10.5 %) Cetuximab ? FOLFIRI RR = 44 %
mTTP = 8 mo
mOS = 16 mo
Gold et al. [13] 63 Metastatic
2nd line
Esophageal AD Cetuximab RR = 5 %
mPFS = 1.8 mo
mOS = 4 mo
Chan et al. [14] 35 Metastatic
2nd line
Gastric, Esophageal AD (34 %),
GEJ AD (23 %)
Cetuximab RR = 3 %
mPFS = 1.6 mo
mOS = 3
Kim et al. [15] 44 Metastatic
1st line
Gastric and GEJ AD Cetuximab ? XELOX RR = 52 %
mPFS = 6.5 mo
mOS = 11.8 mo
Lordick et al.
[16]
52 Metastatic
1st line
Gastric and GEJ AD (48 %) Cetuximab ? FUFOX RR = 65 %
mTTP = 7.6 mo
mOS = 9.5 mo
Moehler et al.
[17]
49 Metastatic
1st line
Gastric and GEJ AD (29 %) Cetuximab ? FI RR = 46 %
mPFS = 9 mo
mOS = 16.5 mo
Rao et al. [18] 35 Metastatic
1st line
randomized
Phase II
Gastric and GEJ AD (60 %) Matuzumab ? ECX RR = 31 %
mPFS = 4.8 mo
mOS = 9.4 mo
Trarbach et al.
[19]
15 Metastatic/
recurrent
Gastric and GEJ AD (27 %) Matuzumab ? PLF RR = 27 %
Schoennemann
et al. [20]
50 Metastatic/
recurrent
Gastric and GEJ AD (86 %) Cetuximab ? irinotecan RR = 14 %
mPFS = 3.3 mo
mOS = 5.5 mo
Tebbutt et al.
[21]
38 Metastatic
1st line
randomized
Phase II
Gastric and GEJ AD (% not
reported) 10 % SCC
Panitumumab ? docetaxel,
cisplatin, fluoropyrimidine
RR = 58 %
mPFS = 6.0 mo
mOS = 10.0 mo
Satoh et al. [22] 83 Metastatic
2nd line
randomized
Phase II
Gastric and GEJ AD (10.4 %) Irinotecan ? nimotuzumab RR = 18.4 %
mPFS = 2.4 mo
mOS = 8.3 mo
EGFR epidermal growth factor receptor, moAbs monoclonal antibodies, AD adenocarcinoma, GEJ gastroesophageal junction, SCC squamous
cell carcinoma, RR response rate, mTTP median time to progression, mOS median overall survival, mPFS median progression-free survival,
FOLFIRI leucovorin, fluorouracil, irinotecan, XELOX capecitabine and oxaliplatin, FUFOX leucovorin, fluorouracil and oxaliplatin, FI
irinotecan, folinic acid and fluorouracile, ECX epirubicin, cisplatin and capecitabine, PLF fluorouracil, leucovorin and cisplatin, mo months
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overexpression was positive in 21 % of gastric carcinomas
and in 33 % of GEJA. The cohort receiving trastuzumab
had a significant improvement in OS (13.8 vs. 11.1 months,
HR 0.74, 95 % CI 0.6–0.91, p = 0.0046), PFS (6.7 vs.
5.5 months) and RR (47 vs. 35 %) (p = 0.0017). In an
explorative analysis, patients with strongly HER2-positive
tumors derived the greatest OS benefit with the addition of
trastuzumab (16.0 vs. 11.8 months, HR 0.68, 95 % CI
0.5–0.83). Based on these data, trastuzumab was approved,
in combination with cisplatin and a fluoropyrimidine, for
first-line treatment of metastatic HER2-overexpressing
gastric or GEJA (Table 3).
Lapatinib ditosylate is a dual anti-EGFR and anti-HER2
TK. This oral drug was investigated in the LOGIC [27] and
TyTAN [28] trials. In the LOGIC study, the primary effi-
cacy population (PEP) comprised all subjects with cen-
trally confirmed tumor FISH amplification. Patients were
randomized to CapeOx with or without lapatinib. The study
failed to meet its primary endpoint (i.e., OS of PEP); mOS
and mPFS were 12.2 vs. 10.5 months, 6.0 vs. 5.4 months in
the experimental arm and control arm, respectively. Pre-
specified subset analyses showed significant OS improve-
ments in patients who were Asian (HR = 0.68) and under
60 years (HR = 0.69). There was no association between
IHC and OS. In patients treated with lapatinib, the toxicity
profile showed increased skin toxicity and grade 3? diar-
rhea (12 vs. 3 %). Based on these negative results, lapatinib
is not recommended outside clinical trials. The TyTAN
study [28] was conducted in Asian HER2 FISH-amplified
patients comparing lapatinib in association with paclitaxel
or not in second-line treatment; OS was not different in the
two arms. However, lapatinib produced OS and PFS
improvement in the small subsets of Chinese patients and
those with IHC3?.
T-DM1 is a conjugate of the MoAb trastuzumab and a
chemotherapy drug, called emtansine; after binding to
Table 2 Phase III randomized clinical trials targeting EGFR
Ref. Patients Setting Primary end
point
Population Therapy Outcome
Waddel et al.
[23]
553 Metastatic
1st line
OS Gastric and GEJ AD
(34 %)
Panitumumab ? mEOX vs.
standard EOX
RR = 42 vs. 46 %
mPFS = 6 vs. 7.4 mo
(p = 0.068)
mOS = 8.8 vs. 11 mo
(p = 0.01)
Lordick et al.
[24]
904 Metastatic
1st line
PFS Gastric and GEJ AD
(16 %)
Cetuximab ± capecitabine and
cisplatin
RR = 30 vs. 29 %
mPFS = 4.4 vs. 5.9 mo
mOS = 9.4 vs. 10.7 mo
EOX epirubicin, oxaliplatin and capecitabine, mo months, mEOX modified epirubicin, oxaliplatin and capecitabine
Table 3 Phase III randomized clinical trials targeting HER2
Ref. Patients Setting Primary
end point
Population Therapy Outcome
Bang et al. [26] 594 Metastatic
1st line
OS Gastric and GEJ AD (18 %) Trastuzumab ±
fluoropyrimidine
and cisplatin
RR = 47 vs. 35 %
mPFS = 6.7 vs. 5.5 mo
mOS = 13.8 vs. 11.1 mo
Hecht et al. [27] 545 Metastatic
1st line
OS Gastric, Esophageal (5 %)
and GEJ AD (9 %)
Lapatinib ± capeOx RR = 53 vs. 40 %
mPFS = 6 vs. 5.4 mo
mOS = 12.2 vs. 10.5 mo
Satoh et al. [28] 261 Metastatic
2nd line
phase II-III
OS Gastric Lapatinib ± paclitaxel RR = 27 vs. 9 %
mPFS = 5.4 vs. 4.4 mo
mOS = 11 vs. 8.9 mo
Kang [29] 415 Metastatic
2nd line
OS Gastric and GEJ AD (% NR) TDM-1 vs. paclitaxel RR = 21 vs. 20 %
mPFS = 2.7 vs. 2.9 mo
mOS = 7.9 vs. 8.6 mo
CapeOx capecitabine and oxaliplatin, mo months, NR not reported
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HER2 receptor on the tumor cell membrane, it delivers the
drug to the cytoplasm. The GATSBY study [29] compared
TDM-1 vs. paclitaxel single agent in second-line therapy;
the primary end point, i.e., OS, was not met, although grade
3 adverse events were lower in the experimental arm (70
vs. 60 %). Dual HER2 inhibition is currently under
investigation in the JACOB phase III study randomizing
cisplatin fluoropyrimidine chemotherapy combined with
trastuzumab with or without pertuzumab [30].
(c) The small-molecule tyrosine kinase inhibitors (TKI),
erlotinib and gefitinib, were also tested as single agent or in
combination with chemotherapy (Table 4). Gefitinib and
erlotinib specifically target the EGFR tyrosine kinase by
binding in a reversible fashion to the adenosine triphos-
phate (ATP) binding site of the receptor to form a
homodimer. By inhibiting the ATP, formation of phos-
photyrosine residues in EGFR is not possible, and the
signal cascades are not initiated.
Stable disease and RR generally were in the magnitude
of 10 %, except in one trial [31]. One trial suggested that
GEJAs were more likely to respond to erlotinib than gastric
cancers [32]; in another trial, responses were seen almost
exclusively in SCC as compared to AD [33]. A possible
explanation is that KRAS and EGFR mutations are
uncommon [31–35] and thus not predictive of response to
TKI in esophageal cancer. In conclusion, the results were
very modest at best for these agents in a metastatic setting.
Targeting angiogenesis
Aberrant tumor angiogenesis has been considered a
potential target in cancer therapy. Currently, there are no
validated biomarkers to select patients for antiangiogenic
therapy, although some candidate surrogate markers of
bevacizumab response have been described. Tumor VEGF
expression was identified as a poor prognosis marker in
esophageal cancer [36]. Strategies developed to modulate
angiogenic signaling were: (1) targeting proangiogenic
factors with moAbs (i.e., the anti-VEGF moAb beva-
cizumab); (2) targeting angiogenic receptors with moAbs
(i.e., the moAb ramucirumab); (3) targeting angiogenic
receptors with TKI (i.e., sunitinib, sorafenib) Table 5.
Depletion of proangiogenic factors
Bevacizumab is a moAb anti-VEGF-A, a protein playing a
significant role in angiogenesis. The drug was tested in the
AVAGAST phase III trial [37], which enrolled 774 patients
(14 % GEJA) and compared the combination of cisplatin
fluoropyrimidine with and without bevacizumab in first-
line treatment. The trial failed to meet the primary endpoint
(OS); subgroup analysis for GEJA was also consistent with
the overall result of the study.
Median OS was 10.1 and 12.1 months in the control and
bevacizumab subsets, respectively (HR 0.87, p = 0.1); on
the other hand, there was a significant improvement in PFS
(5.3 vs. 6.7 mo) and RR (37 vs. 46 %) in the experimental
arm. The bevacizumab safety profile was as expected, with
increased rates of hypertension (6.2 vs. 0.5 %) and gas-
trointestinal perforation (2.3 vs. 0.3 %). Traslational
research [38] evaluated the efficacy of bevacizumab with a
comprehensive prospective biomarker analysis. High
plasma VEGF-A levels and low neuroplin-1 expression
were negative prognostic factors, although these patients
were more likely to respond to bevacizumab. Conse-
quently, plasma VEGF-A and tumor neuropilin-1 seem
potential biomarker candidates for predicting clinical out-
come; however, the finding needs confirmation in
prospective studies. In a recent phase II study, 39 patients
Table 4 Phase II studies with TKI (erlotinib, gefitinib)
Ref. Patients Setting Population Therapy Outcome
Wainberg et al. [31] 33 Metastatic
1st line
Gastric and esophageal AD Erlotinib ? FOLFOX 6 RR = 51.5 %
mPFS = 5.5 mo
mOS = 11 mo
Dragovich et al. [32] 70 Metastatic
1st line
Gastric and GEJ AD Erlotinib RR = 9 %
Ilson et al. [33] 30 Metastatic
2nd line
Esophageal and GEJ AD and SCC Erlotinib RR = 8 %
Adelstein et
al [34]
58 Metastatic
1st/2nd line
Esophageal and GEJ AD and SCC Gefitinib RR = 7 %
mOS = 5.5 mo
Ferry et al. [35] 27 Inoperable 1st line Esophageal AD Gefitinib RR = 11 %
mOS = 4.5 mo
mPFS = 1.9 mo
FOLFOX 5-fluorouracil, leucovorin and oxaliplatin, mo months
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(66 % distal esophageal and GEJ adenocarcinoma)
received bevacizumab with a modified FOLFOX regimen.
RR was 56 %, mTTP 8.2 months and mOS 15.2 months;
12.8 % of deep venous thromboembolism and pulmonary
embolism was reported [39]. A phase Ib/II study, testing
weekly docetaxel and cisplatin together with capecitabine
and bevacizumab, was closed early, after the accrual of 22
patients because of the accumulation of toxicity-related
deaths [40].
Targeting angiogenic receptors with moAbs
Ramucirumab is a human IgG1 moAb VEGF-receptor 2
antagonist. The REGARD [41] and RAINBOW [42] ran-
domized phase III clinical trials tested the efficacy of
ramucirumab in advanced/metastatic pretreated gastric or
GEJA patients with ECOG PS = 0–1; OS, the primary end
point, was met in both studies. In the REGARD trial [41],
355 patients (25 % GEJA) were randomized (2:1) to
receive ramucirumab or placebo. In the ramucirumab arm,
median OS was 5.2 vs. 3.8 months (HR 0.78, 95 % CI,
0.60–0.99; p = 0.047), median PFS was 2.1 vs. 1.3 months
(HR 0.48, p\ 0.0001), and the disease control rate was 49
vs. 23 % (p\ 0.0001). In the subgroup analysis for GEJA,
significance was maintained only for PFS (HR 0.39, 95 %
CI 0.23–0.65) and not for OS. While rates of adverse
events were mostly similar between groups, rates of
hypertension were higher in ramucirumab-treated patients
(16 vs. 8 %). Outcome and toxicity profiles were similar in
patients B65 years or older [43]. Ramucirumab has been
approved by FDA as a single agent for the treatment of
patients with advanced or metastatic, gastric or GEJA
progressing on or after prior fluoropyrimidine-or platinum
containing chemotherapy Table 6.
In the RAINBOW study [42], 665 patients were ran-
domized (1:1) to paclitaxel with or without ramucirumab.
In the ramucirumab arm median OS was 9.6 vs. 7.4 months
(HR 0.81, 95 % CI 0.67–0.96; p = 0.017), median PFS
was 4.4 vs. 2.9 months (HR 0.63, 95 % CI 0.54–0.75;
p\ 0.0001), and RR was 28 vs. 16 % (p = 0.0001). At
multivariate analysis, factors significantly associated with
OS were geographical region, ECOG PS, weight loss,
Table 5 Phase II studies targeting angiogenesis with TKI (sunitinib, sorafenib, regorafenib, apatinib)
Ref. Patients Setting Population Therapy Outcome
Moehler MH et al.
[49]
91 (45 sunitinib)
Randomized phase II
Metastatic
2nd/3rd line
Gastric and GEJ AD
(50 %)
Sunitinib ± FOLFIRI RR = 20 %
mPFS = 3.6 mo
mOS = 10.5 mo
Bang et al. [50] 78 Metastatic
2nd line
Gastric and GEJ AD
(6.4 %)
Sunitinib RR = 2.6 %
mPFS = 2.3 mo
mOS = 6.8 mo
Moehler M et al.
[51]
51 Metastatic
2nd line
Gastric and GEJ AD
(22 %)
Sunitinib RR = 3.9 %
mPFS = 1.3 mo
mOS = 5.8 mo
Martin-Richard
et al. [52]
40 Metastatic
2nd line
Gastric and GEJ AD
(27.5 %)
Sorafenib ?
oxaliplatin
RR = 2.5 %
mPFS = 3 mo
mOS = 6.5 mo
Sun et al. [53] 44 Metastatic
1st line
Gastric and GEJ AD (%
not reported)
Sorafenib ?
docetaxel/cisplatin
RR = 41 %
mPFS = 5.8 mo
mOS = 13.6 mo
Pavlakis et al.
[54]
152
Randomized phase II
Metastatic
2nd–3rd line
Gastric and GEJ AD
(37 %)
Regorafenib vs.
placebo
RR = NR vs. NR
mPFS = 11.1 vs.
3.9 wks
mOS = 25 vs.
19.4 wks
Li et al. [56] 273
Randomized phase III
Metastatic after
2nd line
Gastric and GEJ AD
(22 %)
Apatinib vs. placebo RR = 2.8 vs. 0 %
mPFS = 2.6 vs.
1.8 mo
mOS = 6.5 vs.
4.7 mo
mo months, NR not reported, wks weeks
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number of metastatic sites, presence of ascites, tumor dif-
ferentiation and prior gastrectomy. The HR for OS
improved after adjusting for these factors (HR 0.745, 95 %
CI 0.62–0.88; p = 0.001) [44]. With the addition of
ramucirumab, QoL was maintained for a longer time, and
more patients reported stable or improved scores [45].
Outcome was similar in Western and Japanese populations,
with a prolonged post-progression survival in Japanese
patients (5.8 vs. 4.4 months), probably due to higher use of
post-discontinuation treatment [46].
Preliminary pharmacokinetic data from patients enrolled
in the REGARD and RAINBOW trials found an associa-
tion of longer PFS, OS, improved HR and increased toxi-
city with higher ramucirumab exposures [47]. To validate
this finding, a phase II randomized trial is investigating the
pharmacokinetics and safety of different ramucirumab
doses in second-line patients (ClinicalTrials.gov Identifier:
NCT 02443883).
A randomized phase II study, enrolling 168 patients (84
in the ramucirumab arm), GEJA 31 %, compared modified
FOLFOX6 plus ramucirumab vs. placebo; mPFS, the pri-
mary end point, was 6.4 vs. 6.7 months and OS 11.7 vs.
11.5 months in the experimental and control arm, respec-
tively. PFS and OS were not influenced by the primary
tumor location (esophageal vs. gastric/GEJ), and the dis-
ease control rate was higher in the ramucirumab arm (85
vs. 67 %, p = 0.008) [48]. The ongoing RAINFALL pla-
cebo-controlled phase III trial compares capecitabine and
cisplatin with or without ramucirumab in first-line therapy
in patients with metastatic gastric or GEJ AD with PFS as
primary end point (ClinicalTrials.gov Identifier: NCT
02314117).
Targeting angiogenic receptors with TKI
Sorafenib, sunitinib and regorafenib are multitargeted TKIs
that inhibit angiogenesis by targeting different signaling
pathways. A randomized placebo-controlled multicentric
AIO phase II trial compared FOLFIRI with or without
sunitinib in pretreated patients. The study failed to meet the
primary end point (PFS); biomarker analysis has been
planned to identify subgroups potentially benefiting from
the addition of sunitinib [49]. Other phase II studies have
been conducted mostly in second line, showing modest
activity: mPFS in the range of 1.3–3.6 months and OS of
about 7 months [50–52]. In front-line therapy, sorafenib in
combination with chemotherapy provided a 41 % RR
(primary end point) [53]. The randomized phase II INTE-
GRATE trial documented a statistically improved PFS with
regorafenib in respect to placebo, but only a trend for OS
[54]. Regional differences were found in the magnitude of
effect, but regorafenib was effective in all regions and
subsets. High plasma levels of IL8, VEGF-A and sVEGFR-
1 showed no convincing evidence of a relation with
adverse prognosis [55]. A broader biomarker study
including markers beyond the VEGF axis and tissue-based
markers is ongoing (Clinical trial information:
ACTRN12612000239864).
Apatinib, a novel vascular endothelial growth factor
receptor 2 TKI, was tested vs. placebo in patients with
advanced gastric or GEJ AD failing at least two lines of
prior chemotherapy in the Chinese population. In this
heavily pretreated but highly selected, subset, the study met
both the co-primary end points (OS, PFS), without signif-
icant differences in QoL [56].
Targeting hepatocyte growth factor receptor
(MET)
MET is a transmembrane TKR for which hepatocyte
growth factor (HGF) is the only known ligand. MET
activation induces complex cellular signaling mediated
through a variety of transduction pathways. Under
Table 6 Studies targeting in mTOR complex
Ref. Patients Setting Population Therapy Outcome
Doi T et al. [66] 53 Advanced/metastatic
2nd line
Phase II
Gastric and GEJ AD (% not reported) Everolimus RR = 0 %
DCR = 56 %
mPFS = 2.7 mo
mOS = 10.1 mo
Ohtsu et al. [67] 650 2nd–3rd line
Phase III
Gastric and GEJ AD (27 %) Everolimus ± BSC RR = 5 % vs. 2 %
DCR = 44 % vs. 22 %
mPFS = 1.7 vs. 1.4 mo
mOS = 5.4 vs. 4.3 mo
mo months, BSC best supportive care
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physiological conditions, MET-driven invasive growth is
tightly regulated and plays a key role in tissue growth and
repair. Aberrant HGF/MET activation occurs in multiple
types of malignancies, including GEJA, via several
mechanisms including overexpression, focal gene amplifi-
cation, gene copy number gain, activating mutations, TKR
transactivation and autocrine or paracrine signaling.
Dysregulated HGF/MET signaling is commonly seen
in GEJA. Approximately 0–10 % of gastric cancers
exhibit MET amplification and up to 60 % MET over-
expression; both amplification and overexpression have
been associated with a more aggressive phenotype and
poor prognosis [57–59]. However, quantification of MET
overexpression is flawed by the different evaluation cri-
teria used; pathologist training and inter-laboratory
quality control are needed for standardization of the
results. A phase II randomized study evaluated anti-HGF
moAb rilotumumab with or without ECX chemotherapy
in 121 non-MET selected naı¨ve patients. Rilotumumab
improved OS in MET-high tumors (11.1 vs. 5.7 months,
HR 0.29, 95 % CI 0.11–0.76, p = 0.012). MET-high
tumor (42 % of evaluable patients) was defined as weak
(1?) or stronger MET IHC staining in [50 % of
malignant cells [60]. The RILOMET-1 phase III study
compared ECX with or without rilotumumab in 609
untreated patients with unresectable/advanced gastric/GEJ
adenocarcinoma, tumor MET-positive by IHC, HER2
negative. The study was stopped early based on an
imbalance in deaths; OS (the primary end point), PFS
and ORR were statistically worse in the rilotumumab
arm. No subgroups seemed to benefit from rilotumumab,
including those with higher percentages of cells
with = 1 ? MET expression. Adverse events were
higher with rilotumumab: peripheral edema, hypoalbu-
minemia, deep vein thrombosis and hypocalcemia [61].
The toxicity profile of rilotumumab in combination with
cisplatin and capecitabine in Japanese patients with
MET-positive gastric/GEJ cancer was consistent with
that of Western patients [62]. Crizotinib, tivantinib and
foretinib failed to demonstrate significant antitumor
activity.
A placebo-controlled phase II study failed to demon-
strate PFS improvement with onartuzumab and FOLFOX6
in first-line patients of whom about 33 % were MET pos-
itive, irrespective of different MET cutoffs [63]. Due to
these negative findings, the phase III study was prema-
turely stopped after enrolling 562 patients out of the 800
foreseen. OS and PFS were similar in the control and
experimental arms (about 11 and 7 months, respectively)
[64].Preliminary data reported an encouraging response
rate in a phase I study testing AMG 337, an investigational
oral MET kinase inhibitor, in MET-amplified patients [65].
Targeting the mammalian target of rapamycin
(MTOR) complex
mTOR is an intracellular serine/threonine kinase that acts
in two protein complexes, TORC1 and TORC2 the mam-
malian target of rapamicin complex. mTOR is involved in
multiple pathways regulating cell survival, motility,
metabolism and protein synthesis. TORC1 is engaged by
the PI3K/AKT signaling pathway, which is frequently
deregulated in cancer. Everolimus is an oral drug inhibiting
the mTOR pathway. A phase II study in chemotherapy-
pretreated patients reported a disease control rate of 56 %
[66] and mOS and mPFS of 10 and 2.7 months, respec-
tively. Everolimus-related pneumonitis (G1–2) was
observed in 15 % of the patients. Based on these data, the
GRANITE-1, a placebo-controlled phase III study of
everolimus in second-/third-line treatment of metastatic
GEJA/GC, failed to prolong OS, the primary end point. In
the intervention arm, the disease control rate was 43 %,
and PFS and OS 1.7 and 5.4 months, respectively. Pneu-
monitis occurred in 3 % of the patients [67].
The ability of everolimus to enhance the activity of
second-line treatment with paclitaxel is currently being
investigated in another phase III trial, rad001-paclitaxel
(RAD-PAC) (AIOSTO-0111, NCT01248403).
Targeting the immune check point pd-1
(programmed death 1)
Malignant cells may evade the immune system control
favoring disease progression. Immune check points (such
as CTLA-4 and PD-1 and its ligands) play a key role
suppressing T-lymphocyte activity. Reversing the inhibi-
tion of adaptive immunity can lead to active stimulation of
patient’s immune system. Pembrolizumab is a selective
MoAb against PD-1. Preliminary data from the phase I
KEYNOTE012 study in heavily pretreated patients showed
31 % RR, with a significant association between the PD-L1
expression level and RR; 6-month OS rate was surprisingly
high (69 %), however at the price of not negligible toxicity
[68, 69]. Based on these results, two phase III studies are
ongoing [ClinicalTrials.gov Identifier: NCT02494583 and
NCT02370498].
Conclusions
In unresectable and metastatic GEJA chemotherapy has
produced a modest impact on OS [1, 70]. The availability
of targeted agents gives new hope to the patients on the
difficult steep path to the cure of this aggressive tumor,
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although to date only a small survival gain has been shown.
Two other major points have to be primarily considered:
clinical results must be balanced against the quality of life
and quality-adjusted survival and the high cost of these
drugs.
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